Get the Stockscreener App
6.12
10.92%
-0.75
After Hours:
6.12
Upstream Bio Inc stock is traded at $6.12, with a volume of 279.42K.
It is down -10.92% in the last 24 hours and down -22.82% over the past month.
See More
Previous Close:
$6.87
Open:
$6.61
24h Volume:
279.42K
Relative Volume:
1.15
Market Cap:
$413.03M
Revenue:
$2.22M
Net Income/Loss:
$-40.51M
P/E Ratio:
-4.7638
EPS:
-1.2847
Net Cash Flow:
$-46.53M
1W Performance:
-20.52%
1M Performance:
-22.82%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$6.115
$6.61
1-Week Range:
$6.115
$7.88
52-Week Range:
$6.115
$29.46
Upstream Bio Inc Stock (UPB) Company Profile
Name
Upstream Bio Inc
Sector
Industry
Phone
781-208-2466
Address
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
6.12 | 413.03M | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
Upstream Bio Inc Stock (UPB) Latest News
Charles Schwab Investment Management Inc. Invests $2.23 Million in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Bank of New York Mellon Corp Invests $607,000 in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
1,660 Shares in Upstream Bio, Inc. (NASDAQ:UPB) Acquired by US Bancorp DE - Defense World
Upstream Bio, Inc.: Promising Outlook with Strategic Positioning and Strong Trial Execution - TipRanks
William Blair Lifts Earnings Estimates for Upstream Bio - Defense World
Long UPB: Upstream Bio’s Robust Financials and Clinical Progress Signal Bullish Reversal - Invezz
Upstream Bio’s Financial Results and Strategic Progress - TipRanks
Promising Developments and Strong Financial Position Drive Buy Rating for Upstream Bio, Inc. - TipRanks
Buy Rating for Upstream Bio: Promising Clinical Progress and Unique Drug Candidate Potential - TipRanks
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - The Manila Times
Form 10-K Upstream Bio, Inc. For: Dec 31 - StreetInsider.com
Upstream Bio, Inc. Completes Enrollment in Phase 2 Trial of Verekitug for Chronic Rhinosinusitis and Raises $293 Million in IPO - Nasdaq
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business ... - Enid News & Eagle
Rhumbline Advisers Invests $275,000 in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
AstraZeneca And GSK Put Spotlight On Nasal Polyps Space - Citeline News & Insights
Upstream Bio to Present at Upcoming March Investor Conferences - GlobeNewswire
Respiratory Disease Biotech Upstream Bio Schedules Two Major Investor Presentations in March - StockTitan
Upstream Bio (UPB) Projected to Post Earnings on Thursday - Armenian Reporter
Global Upstream Bioprocessing Equipment Market Poised for - GlobeNewswire
Upstream Bioprocessing Market Size to Reach $105.46 Bn by 2034 - BioSpace
Upstream Bio Inc (NASDAQ: UPB) – An Analysis Is What You Need - Stocks Register
‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public - BioPharma Dive
Critical Alert: Auto Industry Hit By Devastating Cyber Attacks60% Incidents Impact Millions - StockTitan
Upstream Bio (NASDAQ:UPB) Reaches New 52-Week LowHere's Why - MarketBeat
Upstream Bio (NASDAQ:UPB) Trading Down 7.3%Here's What Happened - MarketBeat
Severe Asthma FDA Approvals, Clinical Trials, Emerging Drugs, Pipeline Insights and Companies | DelveInsight - The Globe and Mail
Upstream Bio (NASDAQ:UPB) Trading 9.4% HigherStill a Buy? - MarketBeat
Waltham biotech plans to raise $150M in IPO this week - The Business Journals
Upstream Bio (UPB) to Release Quarterly Earnings on Thursday - MarketBeat
Moody Aldrich Partners LLC Makes New Investment in Upstream Bio, Inc. (NASDAQ:UPB) - MarketBeat
Chronic Rhinosinusitis with Nasal Polyps Pipeline 2024: FDA - openPR
Upstream Bio (NASDAQ:UPB) Sets New 52-Week Low – Time to Sell? - Defense World
Upstream Bio (NASDAQ:UPB) Trading Down 3.9%Time to Sell? - MarketBeat
Upstream Bio (NASDAQ:UPB) Sets New 52-Week LowTime to Sell? - MarketBeat
Modest Final Quarter Completes Shaky Biotech IPO Comeback For 2024 - News & Insights
Upstream Bio (NASDAQ:UPB) Trading Down 10.4%Time to Sell? - MarketBeat
Upstream Bio (NASDAQ:UPB) Sets New 1-Year LowWhat's Next? - MarketBeat
Sionna Therapeutics Appoints Dr. Marcella Kuhlman Ruddy and Dr. Jo Viney to its Board of Directors - citybiz
Upstream Bio (NASDAQ:UPB) Stock Price Down 7%What's Next? - MarketBeat
Upstream Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Upstream Bio Inc Stock (UPB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):